Skip to content
DataLookout
Menu

TRICAV-IINCT06458907

A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Start date pushed from Oct 2026 to Nov 2026
    • Site contacts updated at 5 of 34 sites
  2. Notable Start date: Aug 2026 to Oct 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 44 words
    • Secondary endpoints: details revised at 7 of 18 entries
    • Site details revised at 5 of 34 sites
    • Publications: details revised at 2 of 2 entries
  3. Minor Study sites: 35 to 34v5
  4. Notable Start date: Apr 2026 to Aug 2026
    • Study title expanded, about 3 words
    v4
  5. Notable Primary completion date: Dec 2025 to Nov 2028v3 Show 10 more changesShow less
    • Start date: Dec 2024 to Apr 2026
    • Eligibility criteria expanded, about 535 words
    • Primary endpoints: 15 to 5
    • Enrollment target: 600 to 780
    • Study sites: 15 to 35
    • Study completion date: Jan 2030 to Nov 2032
    • Interventions: Optimal medical therapy (Drug), TricValve® Transcatheter Bicaval Valve System (Device) to Optimal medical therapy (Drug), TricValve System (Device)
    • Secondary endpoints: 6 to 18
    • Study description expanded, about 15 words
    • Study title expanded, about 6 words
  6. Notable Eligibility criteria expanded, about 17 words
    • Primary endpoints revised (15)
    • Study description expanded, about 4 words
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Randomized Cohort: Caval Reflux (CR) grade reduction
Timeframe: 6 months
Randomized Cohort: Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement
Timeframe: 6 months
Randomized Cohort: Rate of Major Adverse Events (MAE)
Timeframe: 30 days
Randomized Cohort: Hierarchical composite endpoint: all-cause mortality, RVAD implantation or heart transplant, tricuspid valve surgery or percutaneous tricuspid intervention, heart failure hospitalizations, KCCQ improvement, NYHA functional class improv
Timeframe: 1 year
Registry Cohort: Rate of Major Adverse Events (MAE)
Timeframe: 30 days

Secondary (18)

Randomized Cohort: Percentage of Device- and/or Procedure-related MAEs
Randomized Cohort: All-Cause mortality and Cardiovascular Mortality
Randomized Cohort: Heart Failure Hospitalizations (HFH)
Randomized Cohort: RVAD Implantation or Heart Transplant
Randomized Cohort: Atrial Fibrillation
Show 13 moreShow less
Randomized Cohort: Quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) .
Randomized Cohort: Changes in symptom status New York Heart Association (NYHA class)
Randomized Cohort: Changes in functional capacity (6-minute walk test, 6MWT).
Registry Cohort: Heart Failure Hospitalization
Registry Cohort: Changes in Quality of life (by Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score).
Roll-In Cohort: Percentage of Device- and/or Procedure-related MAEs
Roll-In Cohort: All-Cause mortality and Cardiovascular Mortality
Roll-In Cohort: Heart Failure Hospitalizations (HFH)
Roll-In Cohort: RVAD Implantation or Heart Transplant
Roll-In Cohort: Atrial Fibrillation
Roll-In Cohort: Quality of life as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ).
Roll-In Cohort: New York Heart Association (NYHA) functional class
Roll-In Cohort: 6-minute walk test (6MWT).

Arms and interventions

TricValve System + Optimal medical therapy (OMT)Experimental

Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy (OMT) in patients with caval reflux and tricuspid regurgitation.

Optimal medical therapy (OMT) AloneActive comparator

OMT alone in patients with caval reflux and tricuspid regurgitation

TricValve Single Arm RegistryExperimental

Single-Arm Registry for Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with OMT in patients with caval reflux and tricuspid regurgitation who are not eligible for randomization

Devices: TricValve System

Drugs: Optimal medical therapy

Sites

34 sites in 1 country